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Rates of complications associated with a second trimester 
genetic amniocentesis were studied in 918 patients, and 
complete infant follow-up was obtained. In 903 singleton 
pregnancies and 15 twin gestations, the procedure was 
• performed under continuous sector scanning guidance 
~ through an attached needle guide. Eight fetal deaths in the 
~ 903 cases occurred at less than 28 weeks after amniocentesis 
f, (0.89%), none within two weeks after the procedure. Only 
~ one fluid was visibly blood contaminated. Comparisons are 
f made with other series from the literature. (Obstet Gynecol ~. 65:751, 1985) 
f ~ 
~. In the early experience with second trimester genetic 
i amniocentesis, large controlled studies documented 
t f the safety of this procedure. I- 3 A later uncontrolled 
study confirmed this in 3000 amniocenteses. 4 With the 
increasing use of ultrasound directions or continuous 
ultrasound guidance,6,7 the known complications asso-
dated with amniocentesis seem to have decreased, 
although this is not the finding in all series.8 
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The rate of fetal loss attributable to amniocentesis 
has never been clear but has been presumed to be 
about 0,5% or less with experienced operators. 9 Ade-
quate documentation still does not exist for a measur-
able decrease in this rate. This is a difficult aspect of 
any study design because of the problems of truly 
representative control groups as well as the differences 
in background ra tes of loss in different series and 
patient populations. The authors report a refinement 
in amniocentesis technique that has resulted in a 
further decrease in amniocentesis complications, prob-
ably including the rate of fetal loss. 
Materials and Methods 
Between September 1981 and September 1983, 918 
women underwent an ultrasound-guided second tri-
mester genetic amniocentesis at the University of Iowa 
Hospitals and Clinics, These procedures were per-
formed with the aid of a needle guide* attached to the 
sector scanning head. A 22-gauge needle routinely was 
used for amniocentesis. Fifteen sets of twins were 
included in the present series. For these latter proce-
dures, indigo carmine was injected into the first aspi-
rated sac using the technique of Elias and associates. 10 
The ultrasound units used were the ADR 2140 Sl:ctor 
Scanner and ADR 4000 S/L. 
The lucite guide shown in Figure 1 was soaked for 15 
minutes in Cidex (activated dialdehyde) between uses. 
Before soaking, the gel was removed from the sites for 
needle insertion, Under supervision of the operator, 
an ultrasound technician performed the initial ultra-
sound examination and, with assistance from the clinic 
nurse coordinator, sterilized and wrapped the sector 
scanner. The sector head was first cleansed with soap 
and water followed by Betadine (povidone-iodine), 
and then was wrapped with a sterile drape, The guide 
was rinsed with sterile saline before attachment. Ap-
proximately five minutes elapsed from completion of 
the initial ultrasound examination to completion of the 
amniocentesis. Figures 2 and 3 show the sterilized 
equipment on the maternal abdomen and an amnio-
centesis through this needle guide. Figure 4 demon-
strates the visualization afforded. 
Seventy-five percent of patients were referred be-
cause of maternal age greater than or equal to 35 at the 
time of delivery. In couples not at risk for a fetus with a 
neural tube defect, the availability of a-fetoprotein 
(AFP) as a screening procedure for these defects was 
discussed, and 96% of such couples elected this evalu-
ation. Maternal serum AFP and amniotic fluid AFP 
were both obtained. 
·CIVCO Medical Instruments Co., Inc., Kalona, IA. 
0029-7844/85/$3.30 751 I I 
.' 
I 
Figure 1. The lower portion of this figure shows the part of the ludte 
guide that has sites for inserting a 22-, 20-, or 18-gauge needle. 
Patient information, indication for the procedure, 
complications, and fetal outcome were compiled and 
computerized. The rate of infant follow-up has been 
100%, as ascertained from the patients and referring 
physicians. Follow-up data were obtained via tele-
phone in the uncommon event that neither patient nor 
Figure 2. The attached guide is shown. The left side houses a 
detachable, rotating insert for use in in utero transfusions or related 
proced ures. 
Figure 3. Withdrawal of amniotic fluid is demonstrated. 
physician provided written follow-up. Further infor-
mation was obtained if any untoward pregnancy out-
come resulted, such as premature birth, stillbirth, or a 
neonate born with malformations. 
Results 
In addition to the 918 patients on whom amniocentesis 
was performed, six women were found to have fetal 
deaths before the anticipated procedure. No alXjnio-
centeses were therefore performed in these cases. In 
five viable Singleton pregnancies, an empty second 
gestational sac also was visualized. Green fluid was 
aspirated in four cases and brown fluid in 11 cases. For 
women referred because of maternal age indication, 
2.2% had fetuses with chromosome abnormalities, not 
including balanced translocations. There were no er-
rors encountered in the chromosome evaluations. No 
fetal neural tube defects were detected, and none were 
seen at birth. The expected incidence in Iowa is ap-
Figure 4. The needle enters the amniotic fluid (AF) at about a Ir 
angle and takes a path between the lines shown. These lines .He 
drawn onto a template that attaches to the cathode ray tube. An 
anterior placenta (P) is shown. Arrows demonstrate needle tip, 
lower, and shaft. 



















proximately one per 1000. II Likewise, no fetal bio-
chemical errors were detected. Congenital malforma-
tions were seen in 2.6% of offspring, and the average 
birth weight of infants greater than 28 weeks' gestation 
was 3460 g. 
Table 1 details the complications in singleton preg-
nancies. Significantly, only one instance of blood-
stained fluid was observed with the guide, and no 
cases of false-positive elevation of amniotic fluid AFP 
secondary to fetal blood contamination occurred. The 
cell culture failed in 0.2% of cases. 
In most instances of failure to obtain fluid (1 %) or 
need for multiple insertions (5.4%), the reason(s) was 
usually obvious when the guide was used. The most 
common reason was tenting of the fetal membranes, a 
known cause for amniocentesis failures. 12 Another 
common cause was uterine contraction, which occurs 
with almost every procedure. When the procedure is 
attempted close to the lateral uterine wall, the needle 
tip can be obstructed after a uterine contraction. 
One infant, born with an enlarged, glaucomatous 
right eye and an opaque cornea, was diagnosed as 
having congenital angle-closure glaucoma. The oph-
thalmologists caring for the child believed this was 
compatible with needle perforation of the globe, al-
though dear fluid was obtained after one insertion and 
the needle was not seen making contact with the fetus. 
Also, the right eyelid showed no evidence of trauma. 
The shortest interval from amniocentesis to fetal 
death was two weeks (Table 2), this being a case 
involving one insertion and a posterior placenta. In no 
instance was there clinical evidence of amnionitis pre-
ceding the pregnancy loss. Two of those eight fetal 
deaths were associated with an elevated maternal 
serum AFP level. 
In addition to the eight fetal deaths less than 28 
weeks after amniocentesis, five other pregnancies 
were associated with fetal death. One was a 1200-g 
Table 1. Complications of Amniocentesis in 903 Singleton 
Pregnancies* 
Pregnancy loss <28 wk 
Blood-stained fluid 
Need to repeat, unable to obtain fluid 
Need to repeat, culture failure 











:'onspicuous needle trauma 1 t 
• The average gestational age by fetal biparietal diameter at the time 
of the tap was 16.6 weeks. Of 117 cases in which the biparietal 
diameter was 15 weeks or less and the procedure attempted, clear 
fluid was aspirated through the guide in all cases with no instances 
for need to return because of inability to obtain fluid or culture failure. 
t Still questionable at this time . 
Table 2. Interval Between Amniocentesis and Fetal Death 
Less Than 28 Weeks 
Tapped at Gestation lost 
(wk gestation) (wk) Comments 
15.5 20 PROM 
17.5 25 IUFO 
15 20 
17 23 IUFO 
16 19 
15.5 17.5 
16 23 Premature labor 
Elevated serum AFP 
18 27 PROM-empty second sac 
Elevated maternal serum AFP 
Brownish fluid 
IUFO intrauterine fetal death; PROM = premature rupture of 
membranes; AFP = a-fetoprotein. 
live-born male who died with multiple anomalies 
shortly after delivery at 29 weeks' gestation. Another 
was a 1336-g male infant of a poorly controlled diabetic 
mother who experienced an intrauterine fetal death at 
28 weeks. A third loss occurred secondary to a placen-
tal abruption at 31 weeks' gestation, with delivery of a 
1440-g stillborn female. Two other infants with no 
obvious anomalies were stillborn at 35 weeks' gesta-
tion and term, respectively. Thus, the total fetal death 
rate in the present group was 1.4% (13 of 903). 
Clear fluid was aspirated from both sacs in 14 of the 
15 twin gestations. In one case a separating membrane 
could not be visualized, and fluid was obtained from 
only one sac. Three sites of needle insertion far re-
moved from the successful first tap yielded bluish 
fluid, although at delivery, a second sac was evident. 
The perinatal outcome was favorable for 29 of 30 
infants, the exception being a trisomy 21 fetus who 
died in utero at about 32 weeks. In addition to this case 
of twin-twin chromosomal discordance, a second set 
also was encountered in which one twin had 47,XXY 
(Klinefelter). 
Of 15 amniocentesis procedures associated with ei-
ther green fluid (four) or brownish fluid (11), the fetal 
outcome was favorable at term or near term in 14 of 
these cases. The exception is the last case listed in 
Table 2. 
RhoGAM was administered to all but one unsensi-
tized Rh negative woman at risk for an Rh positive 
fetus. This patient elected not to have RhoGAM after 
discussing the rationale for its use and the theoretic, 
though unproved, fetal risks from this medication. 
There was also one case of maternal sensitization after 
amniocentesis in a woman who received RhoGAM but 
became sensitized to E antigen. 
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Discussion 
Although a concurrent control group for the present 
study did not exist, a previous series from this institu-
tion reported an equivalent number of procedures in 
which the needle guide technique was not used. 13 One 
obstetrician (MV) also participated in that series as one 
of two operators. In 911 singleton pregnancies in the 
previous study from January 1977 to December 1980, 
the fetal death rate at less than 28 weeks after amnio-
centesis was 1.9% compared with 0.89% in the 903 
singleton pregnancies in the present series. The 1.9% 
loss rate compares favorably with other series from the 
early 1980s.14.1 5 
The total rate of fetal death in the current group in 
whom the guide was used for singleton pregnancies 
was 1.4%. If the 15 twin gestations are added, includ-
ing the third trimester death of a trisomy 21 fetus, the 
total fetal loss rate is 1.5%. Three other US studies have 
specified total rates of fetal loss and the periods over 
which these losses occurred. The National Institute of 
Child Health and Human Development collaboration 
study reported a total fetal death rate of 3.5% after 
amniocentesis. In that series, the loss from weeks 15 to 
29 was 2.8%.1 Hill et aIlS reported a 3.03% rate of fetal 
loss in their series, of which 0.89% occurred in the first 
week after the procedure. Porreco et al 14 experienced 
2.84% total losses, with a 2.07% loss rate occurring 
between the time of amniocentesis to 28 weeks. 14 
Most reports either do not address the incidence of 
bloody amniotic fluids obtained or, if cited, do not 
mention the possible relationship to subsequent fetal 
outcome. This may be related to the conclusion of the 
National Institute of Child Health and Human Devel-
opment study that indicated that bloody amniotic fluid 
was not related to fetal loss. A large well-controlled 
study by Ron and colleagues 16 documents what seems 
intuitively would be the case: Bloody amniotic fluid 
caused by the procedure does significantly increase 
fetal loss. In that study, the controls with clear fluid 
had a rate of fetal loss of 1.7%, but the fetal loss rate 
was 6.6% when maternal blood contaminated the 
amniotic fluid and was 14.3% with fetal blood contami-
nation. Bloody fluid also increases the incidence of 
culture failure l7 and is associated with increases in 
maternal serum AFP after the test. I~ The fetal death 
rate has been reported to be higher with an amniocen-
tesis-induced rise in maternal serum AFP. 19-21 
The frequently reported increase in fetal loss rate 
after withdrawal of greenish or brownish fluid4.13.22 
was not observed, as only one in 15 cases with this 
finding was associated with a fetal loss in the present 
study. There is recent evidence that greenish fluid is 
not meconium but rather old blood. 23 Based on hemo-
globin content, it would appear that a significant 
fraction of this can represent fetal blood. 
The case of possible ocular trauma in a male f 
d 
ems 
secon ary to the procedure warrants further d' 
. U' I . ISCUS_ 
slon. mocu ar blIndness believed related to a se 
. " cond 
tnmester ammocentesls has been reported by M . 
d B h'4 . enn an. eyt. - In their case, however, the first 2 roL of 
flUId were contaminated with fetal blood. Congenital 
glaucorr:a occu.rs in about one of 10,000 newborns and 
predominates In males with a ratio of about 3: 1.25 
With the visu~l~zation afforded by the described 
method, needle Injury was not evident in any oth 
. ~hh . ~ c~se In w:c t e gUide was used, if indeed eye trauma 
~ld occur In the present case. A stable physical connec-
hon of the sector head with the guide has the advan-
tage Of. maintaining the needle in the plane of the 
sector Image (about 0.2 mm width), although with 
beveled needle tips, the needle occaSionally deviates 
out of the scanning plane. Thus, fetal injury can 
potentially occur if the needle is advanced without it 
b 
. S 
emg constantly visualized. This requires the sono-
?rapher to make minor adjustments of the sector head 
In response to ut~rine d~namics, maternal breathing, 
and needle bendmg. ThiS has been a relatively easy 
~ask to learn, and seems less capricious than attempt-
Ing to track a needle not in the direct path of the 
scanning plane. In a recent study of continuous ultra-
sound visualization of the procedure without this 
physical connection, the needle was seen striking the 
fetus in 27 of 131 procedures. 26 
Improvements in amniocentesis technique such as 
reported herein will continue to be important. Many 
states are, or will soon begin, screening for fetal neural 
tube defects by means of maternal serum APP testing. 
The risklbenefit ratio has been questioned for this 
screening. It has been calculated that the rate of 
intended fetal losses (elective abortions, assuming all 
fetuses with neural tube defects would be aborted) to 
unintended fetal losses (procedure-related) would be a 
ratio of about 4: 1 Y Nontraumatic amniocentesis pro-
cedures will be important in the acceptance of maternal 
serum AFP screening, and indeed to second trimester 
testing in general. An often-cited reason for a couple to 
decline amniocentesis is the low but definite risk of 
fetal loss. 
I~ concl~sio.n, the authors have reported a large 
senes of IDldtnmester genetic amniocenteses in which 
continuous ultrasound guidance has been associated 
with the lowest rate of fetal death yet reported. This 
technique, or similar variants, would now seem appro-
priate for widespread use. 
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